Noven Tries To Block Watson's Generic Daytrana

Law360, New York (October 13, 2011, 9:21 PM EDT) -- Noven Pharmaceuticals Inc. on Thursday filed a patent infringement suit seeking to stop Watson Pharmaceuticals Inc. from marketing generic versions of Daytrana, Noven’s patch treatment for children with attention deficit hyperactivity disorder.

Noven said in a statement that it had filed a complaint in New Jersey federal court alleging Watson had filed an abbreviated new drug application with the U.S. Food and Drug Administration to make generic versions of Daytrana, violating Noven's patents.

The patents are valid until 2018, according to the statement.

“The lawsuit reflects...
To view the full article, register now.